PUBLISHER: The Business Research Company | PRODUCT CODE: 1942758
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942758
Drug-device combinations refer to therapeutic and diagnostic products that combine a medical device with a drug, facilitating localized drug administration, precise drug targeting, and personalized therapy. These combinations create a unified entity, physically and chemically, packaged together in a single package. Drug-device combinations play a crucial role in clinical development, enabling the delivery of drugs to specific locations in the body.
The primary types of drug-device combination products include auto-injectors, microneedle patches, digital pills, smart inhalers, drug delivery hydrogels, drug-eluting lenses, and other products. These products find applications in various medical fields such as orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, among others. The end users of drug-device combination products include clinics, hospitals, home care settings, ambulatory care centers, and others. These products are distributed through direct tenders, retail sales, and other distribution channels.
Tariffs are influencing the drug device combination market by increasing costs of imported polymers, sensors, electronic components, and precision molding equipment used in auto-injectors, smart inhalers, and digital pills. Healthcare manufacturers in North America and Europe are most affected due to reliance on global component sourcing, while Asia-Pacific faces pricing pressure on device exports. These tariffs are increasing production costs and lengthening commercialization timelines. However, they are also encouraging domestic device manufacturing, localized assembly, and innovation in cost-efficient combination product designs.
The drug device combination market research report is one of a series of new reports from The Business Research Company that provides drug device combination market statistics, including drug device combination industry global market size, regional shares, competitors with a drug device combination market share, detailed drug device combination market segments, market trends and opportunities, and any further data you may need to thrive in the drug device combination industry. This drug device combination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug device combination market size has grown rapidly in recent years. It will grow from $144.22 billion in 2025 to $161.48 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, expansion of injectable drug therapies, growth in biologics development, rising use of self-administration devices, increasing regulatory approvals for combination products.
The drug device combination market size is expected to see rapid growth in the next few years. It will grow to $249.33 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising investments in digital therapeutics, expansion of home-based drug delivery, growing demand for connected medical devices, increasing focus on precision drug targeting. Major trends in the forecast period include increasing adoption of smart drug delivery devices, rising demand for patient-centric combination products, growing integration of digital monitoring in drug delivery, expansion of targeted therapy delivery systems, enhanced focus on personalized treatment platforms.
The rising incidence of chronic conditions is expected to propel demand for drug-device combination products. Chronic conditions are illnesses that typically last a year or more and can limit daily activities, require ongoing medical attention, or both, including conditions such as cardiovascular disease and diabetes. Drug-device combination products support the management of these long-term conditions by pairing specific pharmaceutical therapies with dedicated delivery systems, which enable accurate dosing, improve patient compliance, and enhance long-term treatment outcomes. For example, in October 2024, a report published by the Centers for Disease Control and Prevention stated that more than 90% of adults aged 65 years and older are living with at least one chronic condition. As a result, the growing burden of chronic diseases is contributing to increased adoption of drug-device combination solutions.
Leading players in the drug-device combination space are prioritizing the development of advanced delivery platforms, including dual-chamber, cartridge-based autoinjectors equipped with integrated needle-isolation and automated reconstitution capabilities. These systems are designed with two separate chambers, one holding a lyophilized drug formulation and the other containing a diluent, allowing controlled mixing immediately before administration. For instance, in June 2025, SHL Medical, a Switzerland-based drug delivery device company, introduced Reunite, a three-step, dual-chamber cartridge autoinjector built on the company's proprietary Needle Isolation Technology to enable automated reconstitution and administration of lyophilized therapies. The device is structured around a dual-chamber cartridge that keeps the needle isolated during storage and preparation, operates through a simple unlock-twist-push workflow to automate mixing and injection, and offers features such as mechanical needle isolation to avoid manual handling, customizable cannula gauge and length to control injection depth and duration, and compatibility with lyophilized biologics that traditionally require complex vial-based preparation.
In May 2023, Closed Loop Medicine Ltd, a UK-based TechBio company focused on developing combination prescription drug and software therapy products, formed a partnership with Pharmanovia. Through this collaboration, Closed Loop Medicine Ltd. aims to advance precision medicine strategies that utilize genetic and molecular profiling to determine the most effective drug combinations for individual patients. Pharmanovia is a UK-based pharmaceutical company.
Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.
North America was the largest region in the drug-device combination market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug device combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The drug-device combination market consists of sales of catheter and advanced wound care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug Device Combination Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug device combination market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug device combination ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug device combination market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.